News

DAYLIGHT is the first of the company's 3 studies and was a randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of a high-intensity dosing regimen of tarcocimab tedromer.

The company also provided an update on tarcocimab development program for the treatment of neovascular age-related macular degeneration and diabetic macular edema.

With lawsuits looming over the issue, the FDA has updated the label on Horizon Pharmaceutical’s drug for thyroid eye disease to include risks associated with hearing loss.

According to the company, Megan Baldwin, PhD, CEO of Opthea Ltd, will provide an overview of the company’s Phase 3 clinical program advancing OPT-302 for the treatment of wet AMD.

According to The Fred Hollows Foundation, an estimated $12 trillion could be added to global output by 2025 if the gender gap was closed in both the workforce and leadership.

According to the University of Barcelona, the agreement between DBGen Ocular Genomics and Novartis will allow the accurate diagnostics of the genetic bases of these two pathologies to be conducted by mass sequencing of gene panels designed by the UB spin-off.

According to The Fred Hollows Foundation, an estimated $12 trillion could be added to global output by 2025 if the gender gap was closed in both the workforce and leadership.

Circumferential canaloplasty, trabeculotomy provide IOP control for 2 years

The surgery provides one of the largest investment returns of any disease intervention.

Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists 2023 annual meeting in Seattle, Washington, including a late-breaking presentation on Vabysmo’s effect on epiretinal membrane (ERM) formation in DME compared to aflibercept.

Francesca Marassi, PhD, and her collaborators have received a $13 million National Institutes of Health grant to study misplaced calcified deposits that are a misunderstood factor in common diseases of aging, including age-related macular degeneration.

Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.

The American Society of Retina Specialists is holding its 2023 annual meeting July 28 through August 1 at the Seattle Convention Center in downtown Seattle.

The DR:EAM trial will evaluate topically delivered OTT166 eye drops in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss.

For visual recovery to occur, there must be photoreceptors left that can be rescued.

Andrew Lee, MD, Andrew Carey, MD, and Elizabeth Fortin, MD, sit down on this episode of the NeuroOp Guru to discuss neuro-ophthalmology, interprofessional eConsults, and whether they provide timely and valuable guidance

Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of July 16, 2023.

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of omidenepag isopropyl ophthalmic solution in the United States.

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

According to 4DMT, the Dose Expansion stage of the PRISM trial is a multicenter, randomized study designed to evaluate the safety and efficacy of 4D-150 at two different dose levels.

New laser is designed to deliver low-energy treatment with ultrashort pulse duration.

The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on 31 July, 2023 in Seattle, Washington.

Harrow states that this transaction will grant US and Canadian commercial rights to six therapeutics, including two non-prescription brands.

The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee has linked Apellis’ pegcetacoplan injection (Syfovre) with a handful of cases of occlusive retinal vasculitis.

According to the ASRS Research and Safety in Therapeutics Committee, ophthalmologists noted instances of intraocular inflammation (IOI) after the initial injection of pegcetacoplan.

Condition is linked to longer resolution times, worse outcomes

SriniVas R. Sadda, MD, discusses being president-elect of ARVO, as well as AI research being conducted at Doheny Eye Institute.